Case Study: Pulmatrix accelerates Phase I inhaled drug development with Quotient Sciences

Pulmatrix accelerates Phase I trials by 12 months with Quotient Sciences

Pulmatrix, a clinical-stage biotechnology company, was seeking to accelerate its Phase I clinical trials for an inhaled therapeutic using its iSPERSE technology. The company was drawn to Quotient Sciences due to the vendor's deep understanding of the UK regulatory environment and its expertise in inhaled drug development, which Pulmatrix had not found with US providers.

By working with Quotient Sciences and leveraging its integrated Translational Pharmaceutics® platform, Pulmatrix was able to streamline its processes. This allowed their drug program to progress more quickly by combining formulation development, manufacturing, and clinical testing within a single program. Quotient Sciences provided a flexible approach that benefited Pulmatrix's development timelines, enabling more efficient planning and execution.

Pulmatrix